In this issue:
Epidemiology & clinical characteristics of checkpoint inhibitor pneumonitis
Clinical outcomes of elderly vs younger patients with limited-stage SCLC
Osimertinib in pretreated, T790M+, advanced NSCLC
Atezolizumab beyond progression in advanced NSCLC
Cisplatin-etoposide + veliparib in extensive-stage SCLC
Predicting survival in resected N2 NSCLC & PORT
Transformation of EGFR-mutant NSCLC to SCLC
Pemetrexed shows promise in recurrent thymoma & thymic cancer
Please login below to download this issue (PDF)